Chester County News and Community Website
WASHINGTON, D.C. — On Thursday, U.S. Senators Bob Casey (D-PA) and Markwayne Mullin (R-OK) introduced the Creating Hope Reauthorization Act, a bipartisan effort aimed at encouraging pharmaceutical companies to develop …
Senate Leaders Push for Reauthorization of Program to Combat Rare Pediatric Diseases Read More
MALVERN, PA — Endo, Inc. this week unveiled a new television commercial and disease awareness campaign, titled “Reminders,” aimed at empowering patients to advocate for their treatment preferences for Dupuytren’s …
Endo Launches “Reminders” Campaign to Empower Patients with Dupuytren’s Contracture Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company focused on rare respiratory diseases, is set to present groundbreaking research at the upcoming American Thoracic Society (ATS) 2024 International …
Savara Inc. to Highlight Advances in Rare Lung Disease Research at ATS 2024 Read More
MALVERN, PA — In a significant advancement for retinitis pigmentosa (RP) treatment, Ocugen, Inc. (NASDAQ: OCGN) has received favorable scientific advice from the European Medicines Agency (EMA) regarding its pivotal …
Ocugen’s Gene Therapy OCU400 Moves Closer to European Market with EMA’s Positive Opinion Read More
PLYMOUTH MEETING, PA — In a significant development for patients with Prader-Willi syndrome (PWS), Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the initiation of a global Phase 3 registrational …
Harmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome Treatment Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to its investigational therapy, CABA-201. This designation …
Cabaletta Bio Receives FDA Orphan Drug Designation for Innovative Autoimmune Disease Therapy Read More
KING OF PRUSSIA, PA — A recent survey sponsored by CSL Behring has illuminated the treatment preferences and concerns of patients living with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare …
Survey Reveals Unmet Needs in Treatment for Rare Nerve Disorder Read More
The U.S. Food and Drug Administration (FDA) recently approved Ogsiveo (nirogacestat) tablets for the systemic treatment of adult patients with progressing desmoid tumors, marking it as the first drug to …
FDA Approves Ogsiveo, First-Ever Drug for Treatment of Desmoid Tumors Read More